Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayCrystal Ball Cloudy for PI3K Inhibitors’ Future in Hematology

In terms of regulation, the PI3K inhibitor medication class had a difficult 2022. Participants in a historic FDA advisory committee meeting in April were warned about dubious safety and efficacy. Less than three months later, the FDA issued a duvelisib (Copiktra) safety warning about mortality rates. As a result, the FDA’s Oncologic Drugs Advisory Committee (ODAC) decided against recommending duvelisib’s approval for the treatment of chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL). Along the way, the FDA also voluntarily withdrew or revoked a number of PI3K inhibitors’ approved indications. Does the medication class have a promising future in the treatment of hematologic malignancies in light of this negative energy?

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form